clinic
syndrom
common
cold
caus
varieti
differ
viral
pathogen
rhinovirus
frequent
caus
ill
may
respons
mani
cold
fall
rhinoviru
epidem
monto
cavallaro
johnston
et
al
arruda
et
al
viral
pathogen
associ
common
cold
coronavirus
respiratori
syncyti
viru
rsv
influenza
viru
parainfluenza
viru
adenoviru
contrast
rhinovirus
agent
either
respons
much
smaller
proport
infect
usual
associ
lower
respiratori
system
symptom
addit
nasal
symptom
characterist
common
cold
monto
cavallaro
surveil
data
suggest
adult
children
experi
rhinoviru
infect
everi
year
gwaltney
et
al
fox
et
al
rhinovirus
caus
infect
yearround
associ
increas
incid
ill
fall
spring
year
onset
common
cold
symptom
typic
occur
day
viral
infect
time
peak
symptom
gener
day
tyrrel
et
al
nasal
obstruct
rhinorrhea
sneez
present
earli
cours
cold
howev
sore
scratchi
throat
frequent
report
bothersom
symptom
first
day
ill
tyrrel
et
al
arruda
et
al
sore
throat
usual
resolv
quickli
second
third
day
ill
nasal
symptom
predomin
cough
associ
approxim
cold
typic
becom
bothersom
symptom
later
ill
nasal
symptom
decreas
sever
gwaltney
et
al
tyrrel
et
al
usual
cold
last
week
although
last
week
gwaltney
et
al
viru
shed
persist
resolut
symptom
viru
may
cultur
subject
week
infect
winther
et
al
although
common
cold
associ
littl
morbid
complic
ill
otiti
media
sinus
exacerb
reactiv
airway
diseas
substanti
medic
impact
spite
medic
signific
common
cold
complic
attempt
develop
effect
treatment
rel
limit
unsuccess
purpos
review
describ
current
statu
treatment
common
cold
gener
recogn
goal
treatment
rhinoviru
cold
includ
amelior
symptom
ill
prevent
persontoperson
spread
infect
prevent
complic
common
cold
current
avail
treatment
limit
symptomat
therapi
although
new
symptomat
treatment
passag
dietari
supplement
health
educ
act
prompt
increas
interest
herbal
medicin
dietari
supplement
common
cold
treatment
substanti
progress
made
develop
antivir
treatment
rhinoviru
although
none
agent
approv
use
treatment
common
cold
final
wide
accept
host
respons
rhinoviru
contribut
ill
associ
infect
recent
advanc
understand
mechan
host
respons
rhinoviru
infect
potenti
reveal
new
target
interrupt
unwant
host
respons
treatment
strategi
ill
rhinoviru
transmit
suscept
individu
either
direct
contact
larg
particl
aerosol
dick
et
al
viru
infect
ciliat
noncili
nasal
epitheli
cell
bardin
et
al
although
nasal
secret
human
volunt
infect
rhinoviru
contain
small
number
rhinoviru
infect
uninfect
ciliat
epitheli
cell
slough
mucosa
turner
et
al
infect
appear
involv
small
proport
epithelium
examin
biopsi
specimen
nasal
epithelium
either
light
electron
microscopi
reveal
consist
lesion
turner
et
al
winther
et
al
winther
et
al
b
absenc
detect
histopatholog
rhinoviru
infect
led
suggest
host
respons
viru
may
play
primari
role
product
common
cold
symptom
turner
et
al
hendley
evalu
hypothesi
produc
compel
evid
host
respons
play
role
rhinoviru
pathogenesi
peripher
white
blood
cell
count
increas
rhinovirusinfect
ill
subject
first
day
viru
challeng
dougla
et
al
increas
white
blood
cell
count
result
increas
concentr
circul
polymorphonuclear
leukocyt
pmn
note
subject
infect
ill
chang
peripher
white
blood
cell
count
similar
pmn
respons
rhinoviru
infect
seen
nasal
mucosa
nasal
secret
winther
et
al
naclerio
et
al
chang
peripher
neutrophil
count
increas
pmn
seen
infect
symptomat
subject
infect
asymptomat
individu
naclerio
et
al
observ
pmn
respons
blood
nasal
mucosa
associ
symptomat
infect
led
effort
understand
origin
inflammatori
respons
initi
studi
conduct
vitro
found
infect
cell
cultur
monolay
rhinoviru
result
elabor
chemoattract
pmn
turner
subsequ
studi
identifi
potent
chemoattract
pmn
least
one
mediat
chemoattract
activ
subaust
et
al
zhu
et
al
studi
coronaviru
respiratori
syncyti
viru
adenoviru
influenza
viru
also
demonstr
elabor
viruschalleng
cell
vitro
choi
jacobi
becker
et
al
subaust
et
al
bruder
kovesdi
kaul
et
al
studi
human
volunt
establish
associ
common
cold
symptom
increas
concentr
present
nasal
secret
subject
symptomat
rhinoviru
infect
children
common
cold
symptom
undetermin
etiolog
noah
et
al
grunberg
et
al
zhu
et
al
turner
et
al
furthermor
experiment
rhinoviru
infect
direct
correl
sever
common
cold
symptom
concentr
nasal
secret
observ
intranas
challeng
normal
subject
produc
symptom
complex
respect
mimic
common
cold
also
provid
support
hypothesi
may
contribut
common
cold
symptom
douglass
et
al
mechan
rhinoviru
challeng
stimul
elabor
examin
cellular
level
attempt
identifi
potenti
target
interrupt
process
although
transcript
activ
gene
somewhat
differ
differ
cell
line
need
activ
nfkb
appear
consist
review
mukaida
et
al
recent
data
suggest
elabor
induc
rsv
influenza
rhinoviru
also
mediat
nfkb
fiedler
et
al
mastronard
et
al
mastronard
et
al
zhu
et
al
biagioli
et
al
knobil
et
al
singl
report
suggest
nfkb
may
essenti
transcript
follow
rhinoviru
infect
kim
et
al
reactiv
oxygen
speci
gener
hydrogen
peroxid
particular
recogn
import
mediat
activ
nfkb
schreck
et
al
mani
induc
nfkb
known
increas
cellular
product
hydrogen
peroxid
nfkb
activ
diminish
cell
line
overexpress
catalas
schmidt
et
al
role
oxid
stress
virusinduc
nfkb
activ
elabor
examin
rhinoviru
influenza
viru
respiratori
syncyti
virusinduc
elabor
mediat
oxid
stress
mastronard
et
al
biagioli
et
al
knobil
et
al
studi
also
shown
treatment
antioxid
inhibit
elabor
respons
challeng
virus
observ
virusinduc
oxid
stress
import
trigger
cellular
respons
varieti
viral
pathogen
led
studi
determin
mechan
oxid
stress
produc
oxid
stress
may
occur
cell
respons
viral
infect
either
inhibit
normal
antioxid
enzym
activ
increas
product
oxid
superoxid
cell
detoxifi
superoxid
dismutas
catalyz
convers
superoxid
hydrogen
peroxid
turn
detoxifi
catalas
glutathion
peroxidas
activ
superoxid
dismutas
catalas
glutathion
peroxidas
inhibit
viru
infect
kaul
et
al
knobil
et
al
suggest
oxid
stress
result
increas
product
prooxid
reactiv
oxygen
speci
ro
reactiv
nitrogen
speci
prooxid
increas
either
speci
would
potenti
result
cellular
oxid
stress
reactiv
nitrogen
speci
gener
action
nitric
oxid
synthas
larginin
produc
reactiv
nitric
oxid
conflict
report
role
nitric
oxid
rhinoviru
infect
rhinovirusinduc
elabor
either
vitro
vivo
mastronard
et
al
sander
et
al
kaul
et
al
contrast
clear
viru
challeng
result
increas
concentr
reactiv
oxygen
speci
cell
mastronard
et
al
biagioli
et
al
knobil
et
al
kaul
et
al
observ
suggest
cellular
oxid
stress
respons
respiratori
viru
infect
due
increas
product
ro
recent
studi
report
evid
nadphoxidas
similar
enzym
sourc
increas
superoxid
respons
viru
challeng
oxid
stress
measur
nitroblu
tetrazolium
dye
reduct
hydrogen
peroxid
product
reduc
follow
viru
challeng
fibroblast
cell
line
defici
one
cytoplasm
compon
nadphoxidas
kaul
et
al
similarli
treatment
normal
fibroblast
cell
line
inhibitor
nadphoxidas
prevent
respons
challeng
rhinoviru
rsv
coronaviru
nadphoxidas
homologu
particip
cellular
signal
report
suh
et
al
banfi
et
al
interest
rhinoviru
stimul
oxid
stress
product
cell
appear
requir
viral
attach
viru
replic
schroth
et
al
kaul
et
al
symptomat
therapi
remain
avail
treatment
common
cold
use
symptomat
therapi
direct
specif
symptom
cold
subject
controversi
smith
feldman
spite
question
efficaci
product
wide
use
kogan
et
al
simon
weinkl
kemper
interest
small
survey
suggest
dietari
supplement
zinc
echinacea
use
frequent
convent
symptomat
treatment
common
cold
kemper
rational
use
zinc
common
cold
treatment
clear
function
rhinoviru
proteas
essenti
enzym
rhinoviru
replic
see
proteas
inhibitor
inhibit
zinc
korant
et
al
cordingley
et
al
although
zinc
found
inhibit
rhinoviru
replic
vitro
evid
antivir
effect
vivo
korant
et
al
alnakib
et
al
farr
et
al
geist
et
al
also
suggest
interact
zinc
host
immun
function
might
provid
benefici
effect
common
cold
symptom
macknin
howev
recent
studi
found
detect
effect
zinc
nasal
secret
concentr
suggest
effect
zinc
due
modul
host
respons
turner
cetnarowski
effect
zinc
treatment
durat
sever
common
cold
symptom
examin
least
differ
studi
sinc
ebi
et
al
alnakib
et
al
dougla
et
al
farr
et
al
smith
et
al
weismann
et
al
godfrey
et
al
mossad
et
al
macknin
et
al
prasad
et
al
result
studi
inconclus
studi
found
effect
zinc
critic
small
sampl
size
use
inadequ
dose
zinc
formul
zinc
might
inactiv
zinc
salt
studi
report
signific
effect
zinc
critic
inadequ
blind
either
use
poorli
match
placebo
activ
prepar
associ
high
incid
advers
effect
recent
studi
adequ
blind
use
formul
zinc
gener
accept
appropri
found
effect
zinc
treatment
natur
cold
modest
effect
induc
cold
turner
cetnarowski
genu
echinacea
consist
nine
speci
three
e
angustifolia
e
pallida
e
purpurea
use
medicin
medicin
prepar
contain
express
juic
e
purpurea
aerial
part
hydroalcohol
tinctur
e
pallida
e
purpurea
root
mainli
use
nonspecif
stimul
immun
system
e
purpurea
aerial
part
e
pallida
root
list
approv
herb
german
commiss
e
support
therapi
cold
chronic
infect
respiratori
tract
blumenth
unit
state
product
made
root
whole
plant
aerial
part
e
pallida
e
angustifolia
e
purpurea
product
usual
formul
powder
plant
materi
alcohol
tinctur
tea
prepar
press
juic
flower
variat
echinacea
speci
plant
part
extract
procedur
manufactur
process
affect
final
product
composit
chemic
constitu
ratio
select
constitu
may
affect
biolog
activ
spite
consider
variat
echinacea
prepar
gener
use
interchang
clinic
studi
pharmacolog
chemic
properti
echinacea
extens
review
bauer
bauer
much
confus
still
exist
concern
pharmacolog
properti
botan
due
inadequ
standard
presenc
contamin
prepar
eg
presenc
mix
echinacea
speci
adulter
parthenium
integrifolium
constitu
echinacea
includ
polar
polysaccharid
glycoprotein
moder
polar
caffeic
acid
deriv
lipophil
polyacetylen
alkamid
glycoprotein
polysaccharid
caffeic
acid
deriv
cichor
acid
alkamid
report
immunostimulatori
activ
stimpel
et
al
bauer
et
al
luettig
et
al
contrast
alkamid
e
angustofolia
e
purpurea
exhibit
antiinflammatori
properti
mullerjak
et
al
thu
sever
substanc
found
echinacea
speci
could
potenti
affect
common
cold
symptom
modul
either
enhanc
suppress
host
immun
respons
stimpel
et
al
cheminat
et
al
bodinet
buescher
burger
et
al
see
et
al
observ
echinacosid
cichor
acid
free
radic
scaveng
protect
free
radic
induc
injuri
facino
et
al
also
interest
light
evid
oxid
stress
may
play
role
virusinduc
elabor
biagioli
et
al
kaul
et
al
efficaci
echinacea
prevent
treatment
viral
respiratori
diseas
evalu
sever
clinic
trial
studi
echinacea
prophylaxi
gener
found
effect
melchart
et
al
melchart
et
al
grimm
muller
posit
result
report
clinic
trial
echinacea
treatment
cold
earli
trial
includ
previou
review
topic
melchart
et
al
three
recent
studi
also
examin
effect
echinacea
product
given
treatment
common
cold
brinkeborn
et
al
studi
patient
took
echinacea
placebo
first
sign
cold
echinacea
use
studi
hydroalcohol
extract
e
purpurea
aerial
part
root
similar
studi
done
volunt
use
squeez
sap
e
purpurea
aerial
part
hoheisel
et
al
studi
report
significantli
reduc
sever
ill
volunt
treat
echinacea
result
studi
must
view
caution
howev
sinc
efficaci
analysi
base
upon
nonspecif
evalu
effect
ie
judg
effect
progress
ill
real
cold
volunt
passiv
report
occurr
ill
studi
report
use
care
standard
symptom
score
method
includ
activ
followup
enrol
patient
henneickevon
zepelin
et
al
analys
includ
evalu
gener
wellb
reveal
statist
signific
benefit
studi
drug
howev
signific
effect
specif
common
cold
symptom
observ
studi
medic
studi
includ
cedar
leaf
indigo
root
addit
echinacea
effect
placebo
blind
report
phytochem
profil
echinacea
prepar
report
previou
studi
convent
symptomat
treatment
common
cold
consist
modest
effect
specif
cold
symptom
firstgener
antihistamin
reduc
rhinorrhea
gwaltney
druce
turner
et
al
topic
anticholinger
ipratropium
bromid
similar
effect
duckhorn
et
al
diamond
et
al
hayden
et
al
second
gener
nonsed
antihistamin
effect
common
cold
symptom
limit
number
studi
gaffey
et
al
berkowitz
tinkelman
observ
absenc
histamin
secret
subject
cold
eggleston
et
al
eggleston
et
al
naclerio
et
al
igarashi
et
al
similar
respons
ipratropium
antihistamin
suggest
effect
antihistamin
rhinorrhea
relat
anticholinerg
rather
antihistamin
properti
drug
oral
adrenerg
agent
reduc
nasal
obstruct
approxim
peak
activ
dressler
et
al
tavern
et
al
topic
agent
greater
activ
akerlund
et
al
modest
therapeut
effect
bothersom
side
effect
symptom
specif
treatment
limit
util
approach
examin
effect
combin
symptomat
antivir
compound
also
report
gwaltney
report
effect
treatment
establish
rhinoviru
infect
combin
naproxen
ipratropium
bromid
gwaltney
effect
combin
appear
greater
effect
usual
seen
avail
common
cold
therapi
studi
effect
treatment
dietari
supplement
echinacea
zinc
common
cold
symptom
produc
inconsist
result
benefit
treatment
remain
unproven
convent
symptomat
treatment
consist
modest
effect
specif
cold
symptom
evid
expect
treatment
prevent
persontoperson
spread
infect
similarli
evid
symptomat
treatment
prevent
develop
complic
common
cold
treatment
children
oral
antihistamin
decongest
combin
prevent
otiti
media
randal
hendley
similarli
use
anticholinerg
agent
oral
topic
nasal
decongest
effect
eustachian
tube
dysfunct
associ
common
cold
turner
darden
pitkaranta
et
al
feasibl
receptor
blockad
first
suggest
observ
abraham
colonno
mani
differ
rhinoviru
serotyp
share
cellular
receptor
abraham
colonno
major
cellular
receptor
rhinoviru
subsequ
identifi
intercellular
adhes
greve
et
al
staunton
et
al
much
smaller
number
serotyp
use
cellular
lowdens
lipoprotein
ldl
receptor
site
viru
attach
hofer
et
al
subsequ
studi
show
rhinoviru
infect
could
prevent
vitro
block
access
receptor
monoclon
antibodi
colonno
et
al
sperber
hayden
base
observ
prophylaxi
intranas
monoclon
antibodi
attempt
hayden
et
al
experiment
cold
volunt
success
studi
total
mgsubject
antiicam
antibodi
given
period
begin
h
end
h
viru
challeng
treatment
regimen
reduc
symptom
viral
shed
time
medic
administ
howev
medic
discontinu
amount
viru
shed
increas
symptom
becam
sever
altern
approach
receptor
blockad
explor
studi
use
truncat
form
creat
delet
transmembran
intracellular
domain
protein
molecul
shown
prevent
infect
rhinoviru
vitro
marlin
et
al
greve
et
al
later
studi
confirm
socal
solubl
icam
prevent
infect
broad
spectrum
rhinoviru
serotyp
varieti
differ
cell
line
crump
et
al
ohlin
et
al
solubl
icam
treatment
subsequ
shown
prevent
infect
rhinoviru
type
chimpanze
treat
mg
sicam
administ
intranas
zero
min
rhinoviru
challeng
huguenel
et
al
human
clinic
trial
sicam
use
experiment
rhinoviru
challeng
model
also
report
studi
sicam
administ
intranas
six
time
day
begin
either
h
h
rhinoviru
challeng
similar
treatment
effect
seen
regardless
time
treatment
relat
viral
challeng
treatment
sicam
effect
incid
infect
reduc
symptom
analysi
combin
treatment
group
frequenc
clinic
cold
reduc
total
symptom
score
reduc
total
nasal
secret
weight
reduc
treat
volunt
also
signific
decreas
quantiti
viru
present
nasal
secret
associ
decreas
concentr
nasal
lavag
fluid
treat
volunt
result
demonstr
reduct
viral
replic
associ
reduct
host
inflammatori
respons
may
benefici
effect
even
infect
establish
result
studi
interest
studi
need
determin
whether
treatment
would
effect
start
onset
symptom
practic
dose
regimen
feasibl
receptor
blockad
minor
receptor
serotyp
also
demonstr
studi
done
solubl
form
ldl
receptor
marlovit
et
al
b
c
case
howev
solubl
receptor
appear
inhibit
infect
caus
aggreg
viru
human
rhinovirus
icosahedr
structur
form
protom
protom
consist
four
protein
design
structur
rhinovirus
resolv
atom
level
crystallograph
techniqu
reveal
canyon
surround
vertex
protom
rossmann
et
al
canyon
form
site
attach
cellular
receptor
viru
olson
et
al
bottom
canyon
hydrophob
pocket
form
associ
pore
canyon
floor
open
channel
lead
interior
viru
hydrophob
pocket
bind
site
socal
capsid
bind
agent
smith
et
al
mechan
antivir
effect
compound
complex
attach
rhinoviru
cellular
receptor
subsequ
movement
viru
host
cell
uncoat
viral
protein
coat
releas
infecti
rna
critic
event
initi
rhinoviru
infect
appear
inhibit
differ
viral
serotyp
agent
ninomiya
et
al
fox
et
al
pevear
et
al
shepard
et
al
larg
number
differ
molecul
bind
hydrophob
pocket
found
antivir
activ
howev
varieti
reason
none
compound
broadli
effect
clinic
studi
review
recent
modif
earlier
molecul
result
compound
pleconaril
favor
pharmacokinet
metabol
stabl
retain
broad
potent
antivir
activ
diana
et
al
pleconaril
evalu
studi
experiment
enteroviru
infect
schiff
sherwood
studi
volunt
given
pleconaril
placebo
h
interv
day
two
hour
second
dose
studi
medic
volunt
challeng
coxsackieviru
intranas
inocul
pleconariltr
volunt
signific
reduct
nasal
mucu
product
total
respiratori
symptom
score
compar
placebotr
volunt
pleconaril
appear
delay
viral
shed
effect
overal
rate
infect
viru
subsequ
studi
pleconaril
treatment
natur
cold
complet
howev
result
studi
yet
publish
rhinoviru
genom
encod
singl
larg
polyprotein
cleav
produc
individu
structur
enzymat
protein
viru
proteas
particip
mani
cleavag
reaction
import
proteas
rhinoviru
replic
fact
activ
site
proteas
appear
highli
conserv
rhinoviru
serotyp
suggest
enzym
potenti
target
antivir
therapi
effort
design
inhibitor
enzym
result
develop
proteas
inhibitor
design
recent
advanc
human
clinic
trial
studi
molecul
vitro
reveal
potent
activ
broad
spectrum
rhinoviru
serotyp
seen
even
drug
ad
cell
sever
hour
viru
infect
inhibit
viru
replic
associ
concomit
inhibit
virusinduc
cytokin
elabor
zalman
et
al
basi
studi
clinic
trial
conduct
experiment
human
rhinoviru
infect
natur
cold
result
studi
yet
publish
preliminari
report
antivir
compound
may
treatment
effect
even
given
onset
ill
suggest
new
effort
antivir
treatment
rhinoviru
cold
repres
substanti
advanc
previou
effort
prior
report
solubl
icam
antivir
therapi
produc
impact
common
cold
symptom
given
infect
nasal
mucosa
establish
spite
promis
result
requir
antivir
drug
inhibit
viru
replic
also
associ
clinic
signific
effect
symptom
pose
formid
barrier
agent
rhinoviru
cold
time
first
detect
symptom
peak
symptom
sever
gener
h
thu
benefici
effect
antivir
treatment
must
gener
detect
background
resolv
ill
second
obstacl
develop
antivir
treatment
common
cold
fact
antivir
agent
virusspecif
mani
differ
virus
associ
common
cold
syndrom
contrast
influenza
virus
produc
rel
distinct
clinic
syndrom
diagnosi
rhinoviru
infect
basi
clinic
syndrom
like
inaccur
inabl
accur
diagnos
infect
clinic
suggest
effect
use
antivir
treatment
like
requir
simultan
avail
pointofus
diagnost
assay
rhinoviru
attempt
develop
assay
unsuccess
date
develop
use
antivir
agent
common
cold
complic
potenti
cost
therapi
unit
state
newli
approv
antivir
therapi
almost
certainli
given
physician
supervis
add
cost
logist
barrier
use
drug
final
gener
benign
selflimit
natur
histori
common
cold
mandat
agent
use
treatment
condit
minim
toxic
side
effect
remain
determin
whether
new
antivir
agent
surmount
barrier
addit
consider
use
antivir
treatment
rhinoviru
infect
potenti
develop
antivir
resist
resist
solubl
icam
develop
readili
vitro
arruda
et
al
natur
occur
resist
capsid
bind
agent
also
document
heinz
et
al
groark
pevear
studi
vivo
howev
suggest
picornavirus
resist
capsid
bind
agent
may
reduc
virul
yasin
et
al
groark
pevear
mutant
resist
proteas
inhibitor
report
limit
experi
agent
spite
repeat
attempt
mani
year
effort
produc
highli
effect
treatment
common
cold
date
unsuccess
effort
focus
primarili
either
inhibit
viral
replic
direct
antagon
end
symptom
observ
varieti
differ
viral
respiratori
pathogen
caus
oxid
stress
cell
elucid
signal
transduct
event
trigger
oxid
stress
may
produc
potenti
new
target
treatment
ill
caus
agent
although
treatment
antioxid
prevent
respiratori
diseas
report
de
flora
et
al
systemat
studi
antioxid
treatment
common
cold
publish
appar
role
nfkb
activ
host
respons
present
anoth
potenti
target
treatment
corticosteriod
appear
inhibit
rhinovirusinduc
nfkb
activ
vitro
papi
et
al
kinin
product
follow
rhinoviru
infect
vivo
farr
et
al
gustafson
et
al
howev
steroid
treatment
increas
viru
replic
effect
common
cold
symptom
farr
et
al
gustafson
et
al
puhakka
et
al
identif
addit
event
signal
transduct
pathway
produc
cellular
respons
viral
pathogen
provid
addit
opportun
interrupt
pathway
modifi
host
respons
infect
final
individu
mediat
found
play
predomin
role
pathogenesi
symptom
specif
inhibitor
mediat
eg
antibodi
may
benefici
impact
ill
mani
question
remain
answer
use
approach
determin
antivir
agent
inhibit
inflammatori
respons
symptom
alreadi
occur
may
associ
limit
effect
resolut
ill
also
clear
whether
host
respons
unwant
associ
symptom
product
target
without
interf
host
respons
necessari
resolut
ill
final
major
impetu
treatment
common
cold
prevent
complic
otiti
media
sinus
exacerb
asthma
major
sourc
morbid
associ
infect
approach
ill
whether
antivir
antiinflammatori
impact
complic
limit
util
common
cold
import
ill
result
econom
impact
common
diseas
morbid
associ
complic
ill
recent
attempt
develop
antivir
treatment
common
cold
repres
substanti
advanc
previou
effort
formid
barrier
remain
overcom
howev
new
product
proven
clinic
use
recent
advanc
understand
pathogenesi
common
cold
symptom
provid
insight
potenti
new
target
treatment
ill
